Literature DB >> 9415511

Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis.

G Heyer1, M Dotzer, L T Diepgen, O H Handwerker.   

Abstract

Itching is a well known side-effect of opiate therapy. To gain insight into the possible contribution of opiate receptors to itching we compared the antipruritic effect of naltrexone (Nemexin), an opiate antagonist, to an H1-receptor antagonist and to placebo. In a double blind cross-over study on 15 healthy volunteers, 25 mg naltrexone or placebo was orally given 60 min prior to a histamine stimulus. In a second, otherwise identical experiment, 10 mg cetirizine, an H1 blocker, or placebo was orally given 12 h before the experiment to the same group of volunteers. Histamine was applied iontophoretically to the forearm skin and the following parameters were assessed thereafter: weal and flare size, itch intensity and the extension of the area of alloknesis ('itchy skin') around the application site. Naltrexone had no effect on the vascular histamine reactions 'weal' and 'flare', whereas cetirizine abolished the weal reactions and greatly diminished the flare reactions. Both naltrexone and cetirizine significantly diminished histamine induced itching. In contrast to placebo and cetirizine, naltrexone abolished alloknesis completely in four of 15 volunteers and in the others alloknesis was greatly reduced after naltrexone. Since vascular reactions to histamine are of peripheral origin, whereas alloknesis depends on central nervous mechanisms, our findings suggest a pronounced centrally mediated action of naltrexone on histamine induced pruritus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415511     DOI: 10.1016/S0304-3959(97)00098-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  17 in total

Review 1.  [Interactions between itch and pain].

Authors:  M Schmelz
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

Review 2.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

3.  Spontaneous itch in the absence of hyperalgesia in a mouse hindpaw dry skin model.

Authors:  Tasuku Akiyama; Mirela Iodi Carstens; E Carstens
Journal:  Neurosci Lett       Date:  2010-08-13       Impact factor: 3.046

Review 4.  A tale of two neurons in the upper airways: pain versus itch.

Authors:  Chih-Feng Tai; James N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2003-05       Impact factor: 4.806

Review 5.  Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development.

Authors:  Ferda Cevikbas; Martin Steinhoff; Akihiko Ikoma
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

Review 6.  Itch mechanisms and circuits.

Authors:  Liang Han; Xinzhong Dong
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

7.  Scratching behavior and Fos expression in superficial dorsal horn elicited by protease-activated receptor agonists and other itch mediators in mice.

Authors:  Tasuku Akiyama; Austin W Merrill; Karen Zanotto; Mirela Iodi Carstens; E Carstens
Journal:  J Pharmacol Exp Ther       Date:  2009-03-17       Impact factor: 4.030

Review 8.  Neural processing of itch.

Authors:  Tasuku Akiyama; E Carstens
Journal:  Neuroscience       Date:  2013-07-24       Impact factor: 3.590

9.  Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.

Authors:  Tasuku Akiyama; Mirela Iodi Carstens; Dorothea Piecha; Sonja Steppan; Earl Carstens
Journal:  Acta Derm Venereol       Date:  2015-02       Impact factor: 4.437

10.  Behavioral model of itch, alloknesis, pain and allodynia in the lower hindlimb and correlative responses of lumbar dorsal horn neurons in the mouse.

Authors:  T Akiyama; M Nagamine; M I Carstens; E Carstens
Journal:  Neuroscience       Date:  2014-02-12       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.